Question/parameter | Frequency | Percentage [95 % CI] |
---|---|---|
Did you spend more or less time to prepare artesunate compared to quinine (N = 24)? | ||
More time | 3 | 12.5 [2.7, 32.4] |
Same time | 3 | 12.5 [2.7, 32.4] |
Less time | 18 | 75 [53.3, 90.2] |
Did you find more or less difficult to prepare artesunate compared to quinine (N = 24)? | ||
More difficult | 3 | 12.5 [2.7, 32.4] |
Same difficulty | 3 | 12.5 [2.7, 32.4] |
Less difficult | 18 | 75 [53.3, 90.2] |
Most cited reasons to support ease of use of injectable artesunate (N = 24) | ||
Rapid way of administration | 15 | 62.5 [40.6, 81.2] |
No accidents related to infusion | 11 | 45.8 [25.6, 67.2] |
Reduced patient’s monitoring time | 5 | 20.8 [7.1, 42.2] |
Time to observe effects of injectable artesunate compared to quinine (N = 31)? | ||
Less time | 29 | 93.6 [78.6, 99.2] |
Same time | 1 | 3.2 [0.1, 16.7] |
More time | 1 | 3.2 [0.1, 16.7] |
Have you noticed any adverse events that you think could be related to artesunate (N = 31)? | ||
Yes | 7 | 22.6 [9.6, 41.1] |
No | 24 | 77.4 [58.9, 90.4] |
Which adverse events did you notice (N = 7) | ||
Decrease of haemoglobin level | 5 | 71.4 [29.0, 96.3] |
Shivering after drug injection | 3 | 42.9 [9.9, 81.6] |
Loss of weight | 1 | 14.3 [0.4, 57.9] |
If you noticed adverse events, would you say that: (N = 7) | ||
They are less than those observed with quinine | 7 | 100 |
They are the same than those observed with quinine | 0 | 0 |
They are more than those observed with quinine | 0 | 0 |
Don’t know | 0 | 0 |
Do you think that the workload has reduced with artesunate compare to quinine (N = 31)? | ||
The workload has diminished | 26 | 83.9 [66.3, 95.4] |
The workload is the same | 4 | 12.9 [3.6, 29.8] |
The workload has increased | 1 | 3.2 [0.1, 16.7] |
What is your level of satisfaction with injectable artesunate (N = 31)? | ||
Very satisfied | 19 | 61.3 [42.2, 78.2] |
Satisfied | 12 | 38.7 [21.8, 57.8] |
Dissatisfied | 0 | 0 |
Most important reasons for being very satisfied/satisfied with injectable artesunate N = 31) | ||
Lack of adverse events | 17 | 54.8 [36.0, 72.7] |
Rapid action of the drug | 15 | 48.3 [30.2, 66.9] |
Easy way to prepare and administer | 9 | 29.0 [12.4, 48.0] |
Injectable artesunate more effective | 9 | 29.0 [12.4, 48.0] |
Work load reduction | 8 | 25.8 [11.9, 44.6] |